Status:
COMPLETED
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
Primary Immune Thrombocytopenia
Eligibility:
All Genders
18+ years
Brief Summary
Description of the use of fostamatinib in patients with PTI in the Andalusian region.
Detailed Description
Fostamatinib is a splenic tyrosine kinase (SYK) inhibitor whose indications include the treatment of chronic primary immune thrombocytopenia (PTI) refractory to first-line treatments. Data from two ph...
Eligibility Criteria
Inclusion
- Patients aged 18 years or older.
- Patients with ITP criteria according to clinical practice guidelines.
Exclusion
- Patients with any medical or psychological condition that prevents them from following the procedures of normal clinical practice as determined by the investigator.
- Subjects with other concomitant hemostatic defects.
- Documented history or clinical evidence of medical conditions (other than ITP) that consider the underlying cause of thrombocytopenia.
- Diagnosis of secondary immune thrombocytopenia.
- Subject has a known allergy to fostamatinib or any of the ingredients included in its formulation.
Key Trial Info
Start Date :
March 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06071520
Start Date
March 1 2023
End Date
June 30 2023
Last Update
October 17 2023
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Puerta del Mar
Cadiz, Cádiz, Spain, 11009
2
Hospital Universitario de Jerez de la Frontera
Jerez de la Frontera, Cádiz, Spain, 11407
3
Hospital de Puerto Real
Puerto Real, Cádiz, Spain, 11510
4
Hospital de Riotinto
Minas de Ríotinto, Huelva, Spain, 21660